To include your compound in the COVID-19 Resource Center, submit it here.

Halozyme increases revenue guidance on BMS, Roche deals

Halozyme Therapeutics Inc. (NASDAQ:HALO) jumped $2.80 (21%) to $15.98 and raised its 2017 revenue guidance on Thursday after announcing two separate licensing

Read the full 221 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE